SEC Form 4 · accession 0001179110-18-008937
IMMUNOGEN INC · IMGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Alan Goldberg
Director
Period of report
Jun 20, 2018
Accepted (ET)
Jun 22, 2018 · 2:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000855654
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Share UnitF1,F3,F2 | $0.00 | Jun 20, 2018 | A | 4,000 | A | Sep 1, 2018 | — | Common Stock | 4,000 | 49,590 | D |
| Stock option (right to buy)F4 | $11.21 | Jun 20, 2018 | A | 18,000 | A | Sep 1, 2018 | Jun 20, 2028 | Common Stock | 18,000 | 18,000 | D |
Explanation of responses
- F1The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- F2The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- F3The deferred share units vest quarterly on 9/1/18, 12/1/18, 3/1/19 and 6/1/19, contingent upon the individual remaining a director as of each vesting date.
- F4Exercisable as to 4,500 shares on 9/1/18, 12/1/18, 3/1/19 and 6/1/19, contingent upon the individual remaining a director as of each vesting date.